May is Asthma Awareness Month. It is a time to focus on a disease that affects more than 250 million people worldwide. Asthma is a chronic lung condition that causes swelling and narrowing of the airways. This leads to symptoms like wheezing, coughing, chest tightness, and shortness of breath. While many people manage asthma with inhalers and medications, there is still no true cure.
A 2025 narrative review published in the Medical Journal of Australia highlights exciting technological advances that may bring us closer than ever to that goal. Researchers believe that scientific innovation, especially in genomics, artificial intelligence, and advanced cell analysis could help define different types of asthma and develop targeted treatments that may one day lead to cures.
Asthma Is Not Just One Disease
Asthma is not a single condition. It includes several different types, sometimes called “endotypes.” An endotype is a subtype of disease defined by its specific biological mechanism.
Asthma can be broadly divided into two major inflammatory types:
- Type 2–high asthma, often linked to allergies
- Type 2–low asthma, which has different underlying pathways
People with asthma may respond very differently to treatment depending on their subtype. Some patients achieve long-term remission, meaning their symptoms largely disappear, with certain biologic medications. Others continue to struggle despite high doses of treatment.
High-Tech Tools to Study Immune Cells
One major breakthrough discussed in the review is spectral flow cytometry. This technology allows researchers to study more than 40 markers on individual immune cells using a small blood sample. Older methods could only analyze a few markers at a time.
This matters because asthma involves many different immune cells working together. By studying these cells in greater detail, scientists can better classify asthma subtypes and match patients with the right therapies.
Another powerful advance is single-cell sequencing. This technique studies the genetic activity of individual cells rather than groups of cells. Before this, researchers could only look at mixed cell populations, which hid important differences.
Single-cell tools have already helped identify new immune cell subtypes involved in allergic asthma. Understanding which exact cells drive inflammation opens the door to more precise treatment targets.
Seeing Disease in Its Natural Environment
Asthma is not just about individual cells. Rather, it is about how those cells interact inside the lungs. That is where spatial transcriptomics and spatial proteomics come in.
These technologies allow scientists to see which genes and proteins are active in specific locations within lung tissue. Instead of removing cells from their environment, researchers can study them exactly where they are in the airway.
This is important because the location of immune cells within lung tissue affects how asthma symptoms develop. Spatial tools help researchers understand how cells communicate and form inflammatory “niches” inside the airways.
The review explains that these methods may revolutionize how we understand immune and epithelial (airway lining) dysfunction in asthma.
Multi-Omics: Putting the Puzzle Together
Modern asthma research does not rely on one type of data. Scientists now combine multiple “omics” approaches:
- Genomics (studying DNA changes)
- Transcriptomics (studying gene activity)
- Proteomics (studying proteins)
- Metabolomics (studying small molecules in cells)
This is called multi-omic integration. By analyzing all these layers together, researchers can better understand the complex networks that cause asthma.
This approach has already helped lead to new biologic medications targeting molecules such as IL-33 and TSLP, which play important roles in type 2 inflammation.
Multi-omics increases the chances of identifying true disease drivers — not just symptoms.
Artificial Intelligence and Digital Twins
With so much data being generated, artificial intelligence (AI) has become essential. AI systems can analyze massive datasets, identify patterns, and predict outcomes faster than traditional methods.
Generative AI and “digital twins” which are virtual models of patients, may transform asthma research. Digital twins could simulate asthma attacks, predict treatment responses, and even replace control groups in future clinical trials.
AI could also help personalize care by predicting which patients are most likely to respond to certain treatments.
However, challenges remain. High costs, data privacy concerns, and the need for strong collaboration between scientists and clinicians must be addressed before these technologies can be widely implemented.
A Future With Precision Diagnoses and Possibly Cure
Asthma remains a major global health burden. Severe asthma affects about 5–10% of patients and significantly reduces quality of life.
But there is hope. Some patients already achieve clinical remission with targeted biologic therapies. As new technologies improve our ability to classify asthma precisely, predict outcomes, and design personalized treatments, the possibility of disease-modifying therapies and possibly even cure may become more realistic.
Breakthroughs in asthma care and research shows incredible progress is being made. With continued innovation, funding, and collaboration, the search for a cure is no longer just a dream.
Source:
Quon S, Johanson TM, Wadhwa R, Faiz A, Flynn A, Anderson GP, et al. Technological advances in the search for a CURE for asthma. Med J Aust. 2025;223(10 Suppl):S36–S41. doi:10.5694/mja2.70084. Available from: https://www.mja.com.au/system/files/issues/223_10/mja270084.pdf
